普樂(lè)沙福作用機(jī)制 - Medchemexpress - MCE中國(guó)

1、Product Data SheetPlerixaforCat. No.: HY-10046CAS No.: 110078-46-1分式: CHN分量: 502.78作靶點(diǎn): CXCR; HIV作通路: GPCR/G Protein; Immunology/Inflammation; Anti-infection儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) Ethanol : 166.66 mg/mL (331.48 mM)DMF : 1 mg/mL (insoluble)DMSO

2、 : 50 mg/kg; LD50, mouse and rat, IV injection: 5.2 mg/kg.PROTOCOLCell Assay 2 U87MG cells are seeded in 96-well plates at the density of 6103 cells in 200 L/well and treated with CXCL12,Plerixafor or with peptide R. MTT (5 g/mL) is added at each time point (24, 48, 72 h) during the final 2 h oftrea

3、tment. After removing cell medium, 100 L DMSO are added and optical densities measured at 595 nm with a LT-4000MS Microplate Reader. Measurements are made in triplicates from three independent experiments2.MCE has not independently confirmed the accuracy of these methods. They are for reference only

4、.Animal Mice3Administration 34 Male C57bl/6 mice (6-7 weeks old, weighing 20 g) are used. The animals are acclimated to the housing environment,which is SPF and had a temperature of 22C and a 12h/12h light/dark cycle for a week. Then, they are randomlydivided into following experimental groups, with

5、 8 mice in each group: normal (no specific intervention),UUO+AMD3100 (mice received UUO surgery and 2 mg/kg AMD3100), and UUO+PBS (mice received UUO surgeryand the same volume of PBS). AMD3100 and PBS are administered via intraperitoneal injection every day untilsacrifice.Rats4The CXCR4 antagonist,

6、AMD3100 dissolved in H2O, is delivered in the type 2 diabetic sand rat model at a dose of 6mg/kg per day for 8 weeks. In complementary studies, the effect of CXCR4 antagonism (AMD3100 6mg/kg/d) onregulatory T cell numbers is examined. For these studies, AMD3100 or vehicle is delivered via minipump f

7、or a periodof one week.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Adv Funct Mater. 2020 Feb. Cell Mol Immunol. 2019 Jul 18. Oncogene. 2019 Jun;38(25):5021-5037. Brain Behav Immun. 2017 Jan;59:322-332. Cell Death Dis. 2017 Jan 19;8(1):e2

8、560.See more customer validations on HYPERLINK www.MedChemE www.MedChemEREFERENCES1. Zabel BA, et al. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7Page 2 of 3 www.MedChemEligands. J Immunol. 2009 Sep 1;183(5):3204-11.2.

9、 Mercurio L, et al. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a humanglioblastoma model. J Exp Clin Cancer Res. 2016 Mar 25;35:55.3. Yang J, et al. Continuous AMD3100 Treatment Worsens Renal Fibrosis through Regulation of Bone Marr

10、ow Derived Pro-Angiogenic Cells Homing and T-Cell-Related Inflammation. PLoS One. 2016 Feb 22;11(2):e0149926.4. Chu PY, et al. CXCR4 Antagonism Attenuates the Development of Diabetic Cardiac Fibrosis. PLoS One. 2015 Jul 27;10(7):e0133616.5. De Clercq E, et al. Mozobil (Plerixafor, AMD3100), 10 years

11、 after its approval by the US Food and Drug Administration. Antivir Chem Chemother. 2019Jan-Dec;27:2040206619829382.6. Seki JT, et al. Chemical Stability of Plerixafor after Opening of Single-Use Vial. Can J Hosp Pharm. 2017 Jul-Aug;70(4):270-275.7. Schols D, et al. HIV co-receptor inhibitors as novel class of anti-HIV drugs. Antiviral Res. 2006 Sep;71(2-3):216-26.McePdfHeightCaution: Product has not been fully valid